Thus, blocking Fyn and Tau interactions with this peptide inhibitor could further validate the outcomes of pharmacological inhibition of Fyn/SFK in an epilepsy model and could identify the Fyn-Tau interaction as a potential therapeutic target in epilepsy. This evidence concerns the gene FYN and epilepsy.